Search Results

You are looking at 21 - 30 of 71 items for :

Clear All
Full access

Gary H. Lyman

product. Filgrastim-sndz has the same protein structure, mass, size, charge, and hydrophobicity as the reference product, and the same mechanism of action of binding to granulocyte colony-stimulating factor (G-CSF) receptors. 2 A phase III trial in 218

Full access

Zachary Veitch, Omar F. Khan, Derek Tilley, Patricia A. Tang, Domen Ribnikar, Douglas A. Stewart, Xanthoula Kostaras, Karen King and Sasha Lupichuk

] stage, nodal status, tumor grade, lymphovascular invasion, hormone receptor status), treatment characteristics (surgery type, receipt of granulocyte colony-stimulating factor [G-CSF], chemotherapy cycles), comorbidity score (using the updated Charlson

Full access

Peter L. Greenberg, Richard M. Stone, Aref Al-Kali, Stefan K. Barta, Rafael Bejar, John M. Bennett, Hetty Carraway, Carlos M. De Castro, H. Joachim Deeg, Amy E. DeZern, Amir T. Fathi, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Ruth Horsfall, Robert A. Johnson, Mark Juckett, Virginia M. Klimek, Rami Komrokji, Lisa A. Kujawski, Lori J. Maness, Margaret R. O'Donnell, Daniel A. Pollyea, Paul J. Shami, Brady L. Stein, Alison R. Walker, Peter Westervelt, Amer Zeidan, Dorothy A. Shead and Courtney Smith

-acting darbepoetin, with or without granulocyte CSF (G-CSF), have been evaluated in the treatment of symptomatic anemia in patients with MDS. Studies predominantly in lower-risk patients with MDS have demonstrated erythroid response rates of 40% and 60% (combined

Full access

Peter L. Greenberg, Eyal Attar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, H. Joachim Deeg, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Steven D. Gore, David Head, Rami Komrokji, Lori J. Maness, Michael Millenson, Margaret R. O’Donnell, Paul J. Shami, Brady L. Stein, Richard M. Stone, James E. Thompson, Peter Westervelt, Benton Wheeler, Dorothy A. Shead and Maoko Naganuma

cytokine support should be considered for refractory symptomatic cytopenias. 82 For example, recombinant human granulocyte colony-stimulating factor (G-CSF) or granulocyte-monocyte colony-stimulating factor (GM-CSF) treatment could be considered for

Full access

Gary H. Lyman and Jessica Malone Kleiner

Dale DC Lyman GH . Meta-analysis of prophylactic granulocyte colony-stimulating factor (G-CSF) in cancer patients receiving chemotherapy [abstract] . J Clin Oncol 2005 ; 23 ( Suppl 1 ): 758 . Abstract 8117 . 14. Lyman GH Lyman CH Agboola

Full access

Jeffrey Crawford

Since the initial approval of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) for clinical use in 1991, our understanding of these agents has grown substantially. Laboratory investigation

Full access

Andrew Wagner

tissue sarcoma patients . Eur J Cancer 2002 ; 38 : 2397 – 2406 . 21. Worden FP Taylor JMG Biermann JS . Randomized phase II evaluation of 6 g/m 2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared

Full access

Gary H. Lyman

) by antibiotics (AB) versus antibiotics plus granulocyte-colony stimulating factor (G-CSF) in small cell lung cancer (SCLC): a randomized phase III study . J Clin Oncol 2004 ; 22 : 14S . 48 Misset JL Dieras V Gruia G . Dose-finding study

Full access

Lauren Nye, Timothy K. Huyck and William J. Gradishar

adjuvant or neoadjuvant therapy in pregnancy include the use of 5-FU, cyclophosphamide, and doxorubicin. Dose-dense chemotherapy is typically not given during pregnancy because of the need for administration of granulocyte colony-stimulating factor (G-CSF

Full access

Jeffrey Crawford, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, David C. Dale, George D. Demetri, Harry P. Erba, James Foran, Alison G. Freifeld, Marti Goemann, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Laura Boehnke Michaud, Sarah C. Miyata, Martin S. Tallman, Saroj Vadhan-Raj, Peter Westervelt and Michael K. Wong

chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study . Am J Clin Oncol 2000 ; 23 : 393 – 400 . 12 Muhonen T Jantunen I Pertovaara H . Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate